Identification

Name
Olopatadine
Accession Number
DB00768  (APRD00310)
Type
Small Molecule
Groups
Approved
Description

Used to treat allergic conjunctivitis (itching eyes), olopatadine inhibits the release of histamine from mast cells. It is a relatively selective histamine H1 antagonist that inhibits the in vivo and in vitro type 1 immediate hypersensitivity reaction including inhibition of histamine induced effects on human conjunctival epithelial cells.

Structure
Thumb
Synonyms
  • Olopatadin
  • Olopatadina
  • Olopatadine
  • Olopatadinum
  • Opatanol
External IDs
AL-4943A / ALO 4943 A / KW 4679
Product Ingredients
IngredientUNIICASInChI Key
Olopatadine Hydrochloride2XG66W44KF140462-76-6HVRLZEKDTUEKQH-NOILCQHBSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act Olopatadine 0.1%Solution0.1 %OphthalmicActavis Pharma Company2013-12-06Not applicableCanada
Act Olopatadine 0.2%Solution0.2 %OphthalmicActavis Pharma Company2014-02-20Not applicableCanada
Olopatadine Hydrochloride NasalSpray665 ug/1NasalPerrigo New York Inc.2015-04-012018-02-01Us
Olopatadine Ophthalmic SolutionSolution0.1 %OphthalmicBeximco Pharmaceuticals Canada LimitedNot applicableNot applicableCanada
PatadaySolution / drops2 mg/1mLOphthalmicLake Erie Medical &Surgical Supply Dba Quality Care Products Llc2012-04-032014-12-31Us
PatadaySolution / drops2 mg/1mLOphthalmicPhysicians Total Care, Inc.2011-01-03Not applicableUs
PatadaySolution / drops2 mg/1mLOphthalmicAlcon, Inc.2007-02-15Not applicableUs
PatadaySolution0.2 %OphthalmicNovartis2011-04-14Not applicableCanada
PatanaseSpray, metered600 ug/1NasalClinical Solutions Wholsesale2008-04-282017-06-26Us
PatanaseSpray, metered665 ug/1NasalPhysicians Total Care, Inc.2009-07-13Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-olopatadineSolution0.1 %OphthalmicApotex Corporation2013-07-26Not applicableCanada
Apo-olopatadineSolution0.2 %OphthalmicApotex Corporation2014-04-10Not applicableCanada
Jamp-olopatadineSolution0.1 %OphthalmicJamp Pharma Corporation2017-10-06Not applicableCanada
Mint-olopatadineSolution0.1 %OphthalmicMint Pharmaceuticals Inc2014-07-29Not applicableCanada
OlopatadineSolution / drops1 mg/1mLOphthalmicGolden State Medical Supply2018-01-08Not applicableUs
OlopatadineSolution / drops1.0 mg/1mLOphthalmicA-S Medication Solutions2017-01-10Not applicableUs
OlopatadineSolution / drops1 mg/1mLOphthalmicAkorn2017-01-10Not applicableUs
OlopatadineSolution / drops2 mg/1mLOphthalmicAkorn2017-12-05Not applicableUs
OlopatadineSolution / drops2 mg/1mLOphthalmicA-S Medication Solutions2017-12-05Not applicableUs
Olopatadine HydrochlorideSpray665 ug/1NasalPerrigo New York Inc2017-06-14Not applicableUs
International/Other Brands
Alchek (Apex) / Alerchek (Indoco) / Allelock (Dae Woong) / Opatanol (Alcon) / Patanol S (Alcon)
Categories
UNII
D27V6190PM
CAS number
113806-05-6
Weight
Average: 337.4122
Monoisotopic: 337.167793607
Chemical Formula
C21H23NO3
InChI Key
JBIMVDZLSHOPLA-LSCVHKIXSA-N
InChI
InChI=1S/C21H23NO3/c1-22(2)11-5-8-18-17-7-4-3-6-16(17)14-25-20-10-9-15(12-19(18)20)13-21(23)24/h3-4,6-10,12H,5,11,13-14H2,1-2H3,(H,23,24)/b18-8-
IUPAC Name
2-[(2Z)-2-[3-(dimethylamino)propylidene]-9-oxatricyclo[9.4.0.0³,⁸]pentadeca-1(15),3(8),4,6,11,13-hexaen-5-yl]acetic acid
SMILES
CN(C)CC\C=C1\C2=CC=CC=C2COC2=C1C=C(CC(O)=O)C=C2

Pharmacology

Indication

For the treatment of ocular itching associated with allergic conjunctivitis.

Associated Conditions
Pharmacodynamics

Used to treat allergic conjunctivitis (itching eyes), olopatadine inhibits the release of histamine from mast cells. It is a relatively selective histamine H1 antagonist that inhibits the in vivo and in vitro type 1 immediate hypersensitivity reaction including inhibition of histamine induced effects on human conjunctival epithelial cells.

Mechanism of action

Olopatadine is a selective histamine H1 antagonist that binds to the histamine H1 receptor. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine. Olopatadine is devoid of effects on alpha-adrenergic, dopamine and muscarinic type 1 and 2 receptors.

TargetActionsOrganism
AHistamine H1 receptor
antagonist
Human
UProtein S100-A1
antagonist
Human
UProtein S100-A12
antagonist
Human
UProtein S100-B
other/unknown
Human
UProtein S100-A13
other/unknown
Human
UProtein S100-A2
antagonist
Human
Absorption

Ophthalmic use of olopatadine usually does not produce measurable plasma concentrations.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

The mono-desmethyl and the N-oxide metabolites have been detected at low concentrations in the urine.

Route of elimination

Elimination was predominantly through renal excretion.

Half life

3 hours

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Olopatadine H1-Antihistamine ActionDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AzelastineOlopatadine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Food Interactions
Not Available

References

Synthesis Reference

Thomas Bader, Hans-Ulrich Bichsel, Bruno Gilomen, Imelda Meyer-Wilmes, Mark Sundermeier, "Polymorphic forms of olopatadine hydrochloride and methods for producing olopatadine and salts thereof." U.S. Patent US20070232814, issued October 04, 2007.

US20070232814
General References
  1. Ohmori K, Hayashi K, Kaise T, Ohshima E, Kobayashi S, Yamazaki T, Mukouyama A: Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride, a new antiallergic drug. Jpn J Pharmacol. 2002 Apr;88(4):379-97. [PubMed:12046981]
  2. Yanni JM, Stephens DJ, Miller ST, Weimer LK, Graff G, Parnell D, Lang LS, Spellman JM, Brady MT, Gamache DA: The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistaminic agent. J Ocul Pharmacol Ther. 1996 Winter;12(4):389-400. [PubMed:8951675]
  3. Ohmori K, Hasegawa K, Tamura T, Miyake K, Matsubara M, Masaki S, Karasawa A, Urayama N, Horikoshi K, Kajita J, Hasegawa M, Taniguchi K, Komada T, Kawamoto Y: Properties of olopatadine hydrochloride, a new antiallergic/antihistaminic drug. Arzneimittelforschung. 2004;54(12):809-29. [PubMed:15646365]
  4. Ohmori K, Ikemura T, Kobayashi H, Mukouyama A: [Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride' (olopatadine), an antiallergic drug]. Nihon Yakurigaku Zasshi. 2001 Jul;118(1):51-8. [PubMed:11496828]
  5. Kaliner MA, Oppenheimer J, Farrar JR: Comprehensive review of olopatadine: the molecule and its clinical entities. Allergy Asthma Proc. 2010 Mar-Apr;31(2):112-9. doi: 10.2500/aap.2010.31.3317. [PubMed:20406593]
External Links
Human Metabolome Database
HMDB0014906
KEGG Compound
C07789
PubChem Compound
5281071
PubChem Substance
46506025
ChemSpider
4444528
BindingDB
50002096
ChEMBL
CHEMBL1189432
Therapeutic Targets Database
DAP001062
PharmGKB
PA450698
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Olopatadine
ATC Codes
S01GX09 — OlopatadineR01AC08 — Olopatadine
AHFS Codes
  • 52:02.00 — Antiallergic Agents
  • 04:00.00 — Antihistamine Drugs
FDA label
Download (114 KB)
MSDS
Download (57.6 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableConjunctivitis, Seasonal Allergic1
2CompletedTreatmentConjunctivitis, Seasonal Allergic3
2TerminatedTreatmentSeasonal Allergic Conjunctivitis to Ragweed1
3Active Not RecruitingTreatmentRhinitis, Allergic, Seasonal1
3CompletedNot AvailableConjunctivitis, Seasonal Allergic2
3CompletedPreventionConjunctivitis, Seasonal Allergic1
3CompletedTreatmentConjunctivitis, Seasonal Allergic7
3CompletedTreatmentConjunctivitis, Seasonal Allergic / Rhinitis, Allergic, Seasonal1
3WithdrawnTreatmentConjunctivitis, Seasonal Allergic1
4CompletedNot AvailableConjunctivitis, Seasonal Allergic1
4CompletedNot AvailableSeasonal Allergic Rhinitis (SAR)1
4CompletedDiagnosticConjunctivitis, Seasonal Allergic2
4CompletedPreventionConjunctivitis, Seasonal Allergic1
4CompletedTreatmentConjunctivitis, Seasonal Allergic10
4CompletedTreatmentPerennial Allergic Rhinitis (PAR)1
4RecruitingTreatmentConjunctivitis, Seasonal Allergic / Conjunctivitis, Vernal1
4WithdrawnTreatmentAllergic Rhinitis (AR)1
4WithdrawnTreatmentConjunctivitis, Seasonal Allergic1
Not AvailableCompletedBasic ScienceAllergic Eye Disease / Conjunctivitis, Seasonal Allergic1
Not AvailableCompletedTreatmentEye Allergies1
Not AvailableTerminatedPreventionHematopoietic Stem Cell Transplant (HSCT) / Malignancies, Hematologic1

Pharmacoeconomics

Manufacturers
  • Alcon inc
  • Alcon laboratories inc
  • Alcon Laboratories, Inc.
Packagers
  • Alcon Laboratories
  • A-S Medication Solutions LLC
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Lake Erie Medical and Surgical Supply
  • Physicians Total Care Inc.
  • Redpharm Drug
Dosage forms
FormRouteStrength
SolutionOphthalmic0.1 %
SolutionOphthalmic0.2 %
Solution / dropsOphthalmic1.0 mg/1mL
SolutionOphthalmic2 mg/1mL
Solution / dropsOphthalmic1.11 mg/1mL
Spray, meteredNasal665 ug/100uL
SprayNasal665 ug/1
Solution / dropsOphthalmic2 mg/1mL
Spray, meteredNasal600 ug/1
Spray, meteredNasal665 ug/1
LiquidOphthalmic0.1 %
Solution / dropsOphthalmic1 mg/1mL
SolutionOphthalmic0.7 %
SolutionOphthalmic7 mg/1mL
Prices
Unit descriptionCostUnit
Patanol 0.1% Solution 5ml Bottle111.2USD bottle
Pataday 0.2% eye drops52.98USD ml
Patanol 0.1% eye drops21.38USD ml
Patanase 0.6% nasal spray3.83USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5116863No1992-05-262010-12-18Us
CA2195094No2002-02-262016-05-03Canada
CA1337603No1995-11-212012-11-21Canada
US6995186Yes2006-02-072024-05-12Us
US7402609Yes2008-07-222022-12-19Us
US8399508Yes2013-03-192023-03-17Us
US7977376Yes2011-07-122023-08-02Us
US8791154No2014-07-292032-05-19Us
US5641805Yes1997-06-242015-12-06Us
US9533053No2017-01-032032-05-19Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)248 °CNot Available
water solubilitySolubleNot Available
logP3.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0313 mg/mLALOGPS
logP3.99ALOGPS
logP0.75ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)3.78ChemAxon
pKa (Strongest Basic)9.76ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area49.77 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity109.55 m3·mol-1ChemAxon
Polarizability37.44 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9747
Blood Brain Barrier+0.6925
Caco-2 permeable+0.7249
P-glycoprotein substrateSubstrate0.8607
P-glycoprotein inhibitor IInhibitor0.5948
P-glycoprotein inhibitor IINon-inhibitor0.8196
Renal organic cation transporterInhibitor0.5413
CYP450 2C9 substrateNon-substrate0.7691
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.7242
CYP450 1A2 substrateInhibitor0.7906
CYP450 2C9 inhibitorNon-inhibitor0.8316
CYP450 2D6 inhibitorInhibitor0.6567
CYP450 2C19 inhibitorNon-inhibitor0.8466
CYP450 3A4 inhibitorNon-inhibitor0.8222
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8676
Ames testNon AMES toxic0.8032
CarcinogenicityNon-carcinogens0.8499
BiodegradationNot ready biodegradable0.6088
Rat acute toxicity2.7626 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8082
hERG inhibition (predictor II)Inhibitor0.5
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0006-0090000000-8e3ac3f01c9b0f33191f
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0007-0090000000-ff327751665292322357
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-00ke-0190000000-4ee44c0a1808c8f38f5f
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-014l-0490000000-af62db4d573fa623449b
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-014l-0690000000-855734373da970ef9009
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-014l-0970000000-10c3777ced99134b4960
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-000i-0009000000-edd957bf788fa0da1cd5
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-000i-0019000000-76019801740d70094185
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-00kk-0593000000-0fb46422a259d1710df5
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-016s-0690000000-d2686bcc07833ec6a7c5
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0fw9-0690000000-20403692a9e2a6948063
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-000i-0009000000-e2c029010aa3133274f8
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-000i-1239000000-a4a1f419cb7782a025ae
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-015a-4890000000-5408d5e1274f9ec8ab42
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00lu-4970000000-5d3cad1a8e8d0b931c62
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00lu-4960000000-d57d90bc4e9b3f57c2fa
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0frx-5960000000-9b3e25cd1765878b5709
MS/MS Spectrum - , positiveLC-MS/MSsplash10-000i-0469000000-a0b3c5cdd43e637acdec

Taxonomy

Description
This compound belongs to the class of organic compounds known as dibenzoxepines. These are compounds containing a dibenzoxepine moiety, which consists of two benzene connected by an oxazepine ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzoxepines
Sub Class
Dibenzoxepines
Direct Parent
Dibenzoxepines
Alternative Parents
Alkyl aryl ethers / Benzenoids / Trialkylamines / Amino acids / Oxacyclic compounds / Monocarboxylic acids and derivatives / Carboxylic acids / Organopnictogen compounds / Organic oxides / Hydrocarbon derivatives
show 1 more
Substituents
Dibenzoxepine / Alkyl aryl ether / Benzenoid / Amino acid or derivatives / Amino acid / Tertiary aliphatic amine / Tertiary amine / Carboxylic acid derivative / Carboxylic acid / Oxacycle
show 12 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
Gene Name
HRH1
Uniprot ID
P35367
Uniprot Name
Histamine H1 receptor
Molecular Weight
55783.61 Da
References
  1. Tamura T, Masaki S, Ohmori K, Karasawa A: Effect of olopatadine and other histamine H1 receptor antagonists on the skin inflammation induced by repeated topical application of oxazolone in mice. Pharmacology. 2005 Dec;75(1):45-52. Epub 2005 Jun 7. [PubMed:15942272]
  2. Ohmori K, Hayashi K, Kaise T, Ohshima E, Kobayashi S, Yamazaki T, Mukouyama A: Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride, a new antiallergic drug. Jpn J Pharmacol. 2002 Apr;88(4):379-97. [PubMed:12046981]
  3. Yanni JM, Stephens DJ, Miller ST, Weimer LK, Graff G, Parnell D, Lang LS, Spellman JM, Brady MT, Gamache DA: The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistaminic agent. J Ocul Pharmacol Ther. 1996 Winter;12(4):389-400. [PubMed:8951675]
  4. Ohmori K, Hasegawa K, Tamura T, Miyake K, Matsubara M, Masaki S, Karasawa A, Urayama N, Horikoshi K, Kajita J, Hasegawa M, Taniguchi K, Komada T, Kawamoto Y: Properties of olopatadine hydrochloride, a new antiallergic/antihistaminic drug. Arzneimittelforschung. 2004;54(12):809-29. [PubMed:15646365]
  5. Ohmori K, Ikemura T, Kobayashi H, Mukouyama A: [Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride' (olopatadine), an antiallergic drug]. Nihon Yakurigaku Zasshi. 2001 Jul;118(1):51-8. [PubMed:11496828]
  6. Roland PS, Ryan MW, Wall GM: Olopatadine nasal spray for the treatment of seasonal allergic rhinitis in patients aged 6 years and older. Expert Opin Pharmacother. 2010 Jun;11(9):1559-67. doi: 10.1517/14656566.2010.485609. [PubMed:20482305]
  7. Kaliner MA, Oppenheimer J, Farrar JR: Comprehensive review of olopatadine: the molecule and its clinical entities. Allergy Asthma Proc. 2010 Mar-Apr;31(2):112-9. doi: 10.2500/aap.2010.31.3317. [PubMed:20406593]
  8. Roland PS, Marple BF, Wall GM: Olopatadine nasal spray for the treatment of allergic rhinitis. Expert Rev Clin Immunol. 2010 Mar;6(2):197-204. [PubMed:20402382]
  9. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
S100 protein binding
Specific Function
Weakly binds calcium but binds zinc very tightly-distinct binding sites with different affinities exist for both ions on each monomer. Physiological concentrations of potassium ion antagonize the b...
Gene Name
S100A1
Uniprot ID
P23297
Uniprot Name
Protein S100-A1
Molecular Weight
10545.755 Da
References
  1. Okada M, Tokumitsu H, Kubota Y, Kobayashi R: Interaction of S100 proteins with the antiallergic drugs, olopatadine, amlexanox, and cromolyn: identification of putative drug binding sites on S100A1 protein. Biochem Biophys Res Commun. 2002 Apr 12;292(4):1023-30. [PubMed:11944917]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Zinc ion binding
Specific Function
S100A12 is a calcium-, zinc- and copper-binding protein which plays a prominent role in the regulation of inflammatory processes and immune response. Its proinflammatory activity involves recruitme...
Gene Name
S100A12
Uniprot ID
P80511
Uniprot Name
Protein S100-A12
Molecular Weight
10574.975 Da
References
  1. Kishimoto K, Kaneko S, Ohmori K, Tamura T, Hasegawa K: Olopatadine suppresses the migration of THP-1 monocytes induced by S100A12 protein. Mediators Inflamm. 2006;2006(1):42726. [PubMed:16864903]
  2. Okada M, Tokumitsu H, Kubota Y, Kobayashi R: Interaction of S100 proteins with the antiallergic drugs, olopatadine, amlexanox, and cromolyn: identification of putative drug binding sites on S100A1 protein. Biochem Biophys Res Commun. 2002 Apr 12;292(4):1023-30. [PubMed:11944917]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other/unknown
General Function
Zinc ion binding
Specific Function
Weakly binds calcium but binds zinc very tightly-distinct binding sites with different affinities exist for both ions on each monomer. Physiological concentrations of potassium ion antagonize the b...
Gene Name
S100B
Uniprot ID
P04271
Uniprot Name
Protein S100-B
Molecular Weight
10712.985 Da
References
  1. Okada M, Tokumitsu H, Kubota Y, Kobayashi R: Interaction of S100 proteins with the antiallergic drugs, olopatadine, amlexanox, and cromolyn: identification of putative drug binding sites on S100A1 protein. Biochem Biophys Res Commun. 2002 Apr 12;292(4):1023-30. [PubMed:11944917]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other/unknown
General Function
Zinc ion binding
Specific Function
Plays a role in the export of proteins that lack a signal peptide and are secreted by an alternative pathway. Binds two calcium ions per subunit. Binds one copper ion. Binding of one copper ion doe...
Gene Name
S100A13
Uniprot ID
Q99584
Uniprot Name
Protein S100-A13
Molecular Weight
11471.095 Da
References
  1. Okada M, Tokumitsu H, Kubota Y, Kobayashi R: Interaction of S100 proteins with the antiallergic drugs, olopatadine, amlexanox, and cromolyn: identification of putative drug binding sites on S100A1 protein. Biochem Biophys Res Commun. 2002 Apr 12;292(4):1023-30. [PubMed:11944917]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Identical protein binding
Specific Function
May function as calcium sensor and modulator, contributing to cellular calcium signaling. May function by interacting with other proteins, such as TPR-containing proteins, and indirectly play a rol...
Gene Name
S100A2
Uniprot ID
P29034
Uniprot Name
Protein S100-A2
Molecular Weight
11116.695 Da
References
  1. Okada M, Tokumitsu H, Kubota Y, Kobayashi R: Interaction of S100 proteins with the antiallergic drugs, olopatadine, amlexanox, and cromolyn: identification of putative drug binding sites on S100A1 protein. Biochem Biophys Res Commun. 2002 Apr 12;292(4):1023-30. [PubMed:11944917]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on November 18, 2018 04:45